CTIS2023-510376-31-00招募中1 期
A phase IIa, randomized, placebo-controlled, double-blind,cross-over study to evaluate safety and efficacy ofsubcutaneous administration of anakinra in patients withcystic fibrosis (ANAKIN) - ANAKI
niversitaetsklinikum Heidelberg AöR0 个研究点目标入组 60 人开始时间: 2024年1月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Age = 18 years (1st cohort). If justified by interim analysis, 18 > age = 12 years (2nd cohort),, Adequate bone marrow function assessed on the basis of: neutrophils >1.5 x 109/L, platelets >100 x 109/L, hemoglobin >9.0 g/dL,, Adequate liver function assessed on the basis of: GGT, ASAT, and ALAT <3 x upper limit of normal (ULN),, Adequate blood clotting assessed on the basis of: aPTT <39 sec., INR <1.2,, Negative serology for HIV (anti-HIV 1/2 IgG/IgM and p24-Ag), HBV (people without history of HepB vaccination: anti-HBs quantitative and anti-HBc IgG/IgM must be negative; people with history of HepB vaccination: anti HBc IgG/IgM negative) and HCV (anti-HCV IgG), negative Interferon-gamma release assay (people with history of a latent infection with Mycobacterium tuberculosis (LTBI), documented adequate treatment of LTBI, and with airway samples negative for Mycobacterium tuberculosis can have a positive test result),, Negative Beta-HCG blood/urine test in women of childbearing potential (of childbearing potential are females who have experienced menarche and are not permanently sterile or postmenopausal (postmenopausal: 12 consecutive months with no menses without an alternative medical cause)),, Use of adequate contraception in sexually active female subjects (sexual abstinence, hormonal contraceptives or intrauterine device)., Informed consent of the patient (if applicable) and/or all legal guardians,, Sufficient fluency of patient and/or his/her representative in German language to comply with study-specific procedures (e.g. to complete required quality of life questionnaires),, Confirmed diagnosis of cystic fibrosis, fulfilling at least one of the following three criteria: a. sweat chloride = 60mEq/L, b. two CF causing mutations in the CFTR gene, c. alterations of transepithelial potential difference of nasal or rectal epithelia typical for CF,, FEV1 = 50 % pred. at screening,, LCI2.5 = 7.05 at screening,, Ability to perform reproducible multiple breath washout and spirometry,, Oxyhaemoglobin saturation of = 90% on room air at screening,, No changes in the medication for cystic fibrosis lung disease for at least 4 weeks prior to the first administration of the IMP of each treatment period (in case of medication changes in Period 1 and/or the washout phase the wash-out may be extended for up to 12 weeks in order to fulfill this criterion),
排除标准
- •Expected non-compliance, i.e. inability or unwillingness to comply with study-specific procedures,, Immunosuppressive treatment due to organ transplantation, rheumatic or autoimmune diseases as well as treatment with Anakinra in the last 3 months before Day 1 of Period 1,, Participation in another interventional trial within the last 30 days prior to screening,, Current oral corticosteroid use,, Current oxygen supplementation,, Current treatment with etanercept,, Medical history of lung transplantation,, Pregnant or nursing females (females of childbearing potential must have a negative pregnancy test at screening),, Known hypersensitivity to hypertonic saline (used for induction of sputum)., Known allergy to anakinra or any ingredient of the pharmaceutical formulation of Kineret®,, Planned immunization with attenuated (live) vaccine(s) during the treatment with the IMP or completed immunization with attenuated (live) vaccine(s) within 4 weeks prior to the first administration of the IMP,, GFR <60ml/min/1.73qm,, History of tuberculosis or repeated detection of non-tuberculous mycobacteria from airway samples in the last 12 months before start of each treatment period,, History of detection of Burkholderia cenocepacia species in the last 12 months before start of each treatment period,, Known colonization with multi-resistant Staphylococcus aureus (MRSA) and/or 4-multiresistant gram negative (MRGN) Pseudomonas aeruginosa is only an exclusion criterion if the treating physician judges that this is an increased risk for the patient,, Acute bronchopulmonary exacerbation (defined by modified Fuchs criteria (23) (see Appendix 1), modification includes all ways of application of an antibiotic (e.g., oral, i.v., inhaled)) within 14 days prior to the screening and before start of each treatment period,, Signs of other active infection within 14 days prior to the screening and before start of each treatment period (clinical symptoms (e.g. burning sensation while urinating, skin, wound or dental infection) and/or fever and/or deterioration of infection-specific laboratory parameters beyond changes driven by the underlying disease),
研究者
相似试验
进行中（未招募）
1 期
Tolerability and Efficacy of Anakinra in patients with cystic fibrosis.Cystic fibrosisEUCTR2016-004786-80-DERuprecht-Karls-University Heidelberg, Medical Faculty52
进行中（未招募）
1 期
Efficacy Study of EG-Mirotin subcutaneously administered in multiple doses on diabetic macular edema in diabetic retinopathy patients.diabetic retinopathy patients having early diabetic macular edema (DME)MedDRA version: 20.0 Level: PT Classification code 10012689 Term: Diabetic retinopathy System Organ Class: 10015919 - Eye disordersEUCTR2014-001351-23-HUEyeGene, Inc30
进行中（未招募）
1 期
Phase II vaccination trial in HIV-1 infected subjectsChronic HIV-1 infectionMedDRA version: 19.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2016-002724-83-BEErasmus MC70
进行中（未招募）
1 期
Phase II vaccination trial in HIV-1 infected subjectsChronic HIV-1 infectionMedDRA version: 19.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2016-002724-83-ESErasmus MC70
已完成
2 期
A phase IIa randomized, placebo controlled, double blinded study to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy.AIDSHIV infection1002146010047438NL-OMON46133Erasmus MC, Universitair Medisch Centrum Rotterdam14